Influencing Public Policy on Research and Clinical Endocrinology
The Endocrine Society produces and signs onto a range of letters to elected officials, Federal agencies, and other legislative and deliberative bodies.
Letter to CMS on Barriers for MDPP Implementation February 15, 2019 | The Endocrine Society joined members of the Diabetes Advocacy Alliance to address barriers to the implementation of the Medicare Diabetes Prevention Program in a comment letter to CMS.
Letter to New Director of the White House Office of Science and Technology Policy
February 1, 2019 | The Endocrine Society welcomes Dr. Kelvin Droegemeier to his new position as White House Director of the Office of Science and Technology Policy and shared the Society's policies and positions related to federal funding of biomedical research, regulatory burdens in research, EDCs, publishing and peer review, and standardization of hormone assays.
Letters of Support for Women's Health Research Day Resolutions
January 24, 2019 | The Endocrine Society and over 20 other organizations wrote Letters of Support for Senator Duckworth and Representative Schakowsky to express support for their introduced "Women's Health Research Day" resolution and applaud their leadership in championing equity in biomedical research.
Endocrine Society Comments on Healthy People 2030 National Objectives
January 17, 2019 | The Endocrine Society provided comments on the Department of Health and Human Services' Healthy People 2030 national objectives. The Society provided general comments on the objectives, as well as some focused on diabetes, nutrition and weight status, osteoporosis, and environmental health.
Representing the Endocrine Society, our members strive to influence public policy related to research and clinical endocrinology issues by testifying before the United States Congress, Federal agencies, and other legislative and deliberative bodies.